Efficacy and Safety of Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Fail to Eltrombopag or Herombopag Treatment: a Single-center, Prospective, One-arm Clinical Trial
Latest Information Update: 28 Feb 2025
At a glance
- Drugs Avatrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus
- Focus Therapeutic Use
Most Recent Events
- 24 Feb 2025 Planned End Date changed from 30 Sep 2024 to 30 Sep 2025.
- 13 Aug 2021 New trial record